Modified cytomegalovirus proteins and stabilized complexes
US-2024383949-A1 · Nov 21, 2024 · US
Antigenic peptide of HSV-2 and methods for using same
US9044447B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9044447-B2 |
| Application number | US-201013262833-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 3, 2010 |
| Priority date | Apr 3, 2009 |
| Publication date | Jun 2, 2015 |
| Grant date | Jun 2, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention provides HSV antigens that are useful for the prevention and treatment of HSV infection, including epitopes confirmed to be recognized by T-cells derived from herpetic lesions. T-cells having specificity for antigens of the invention have demonstrated cytotoxic activity against cells loaded with virally-encoded peptide epitopes, and in many cases, against cells infected with HSV. The identification of immunogenic antigens responsible for T-cell specificity provides improved anti-viral therapeutic and prophylactic strategies. Compositions containing antigens or polynucleotides encoding antigens of the invention provide effectively targeted vaccines for prevention and treatment of HSV infection.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of enhancing proliferation of herpes simplex virus type 2 (HSV-2)-specific T cells from a subject expressing human leukocyte antigen (HLA) type B08 comprising contacting the HSV-specific T cells with a polypeptide consisting of AFEDRSYPAVFYLLQ (SEQ ID NO: 12) and up to 15 amino acids of adjacent native sequence of U L 19 (SEQ ID NO: 6), and wherein said T cells are contacted with said polypeptide in an amount sufficient to enhance proliferation of s…
Assignees
Inventors
Classifications
Human Necessities · mapped topic
Chemistry & Metallurgy · mapped topic
- A61K39/245Primary
Human Necessities · mapped topic
Chemistry & Metallurgy · mapped topic
- A61K9/0019Primary
Human Necessities · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9044447B2 cover?
- The invention provides HSV antigens that are useful for the prevention and treatment of HSV infection, including epitopes confirmed to be recognized by T-cells derived from herpetic lesions. T-cells having specificity for antigens of the invention have demonstrated cytotoxic activity against cells loaded with virally-encoded peptide epitopes, and in many cases, against cells infected with HSV. …
- Who is the assignee on this patent?
- Corey Lawrence, Laing Kerry J, Wald Anna, and 3 more
- What technology area does this patent fall under?
- Primary CPC classification A61K39/245. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jun 02 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).